- Home
- STHO vs TCRX Comparison
STHO vs TCRX Comparison
Compare STHO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- TCRX
- Stock Information
- Founded
- STHO N/A
- TCRX 2018
- Country
- STHO United States
- TCRX United States
- Employees
- STHO N/A
- TCRX N/A
- Industry
- STHO Real Estate
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- TCRX Health Care
- Exchange
- STHO Nasdaq
- TCRX Nasdaq
- Market Cap
- STHO 112.7M
- TCRX 123.7M
- IPO Year
- STHO N/A
- TCRX 2021
- Fundamental
- Price
- STHO $7.98
- TCRX $1.97
- Analyst Decision
- STHO
- TCRX Strong Buy
- Analyst Count
- STHO 0
- TCRX 5
- Target Price
- STHO N/A
- TCRX $9.40
- AVG Volume (30 Days)
- STHO 42.3K
- TCRX 468.4K
- Earning Date
- STHO 11-04-2025
- TCRX 11-11-2025
- Dividend Yield
- STHO N/A
- TCRX N/A
- EPS Growth
- STHO N/A
- TCRX N/A
- EPS
- STHO N/A
- TCRX N/A
- Revenue
- STHO $113,989,000.00
- TCRX $6,961,000.00
- Revenue This Year
- STHO N/A
- TCRX $255.18
- Revenue Next Year
- STHO N/A
- TCRX N/A
- P/E Ratio
- STHO N/A
- TCRX N/A
- Revenue Growth
- STHO N/A
- TCRX N/A
- 52 Week Low
- STHO $6.06
- TCRX $1.02
- 52 Week High
- STHO $13.50
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- STHO 38.46
- TCRX 55.22
- Support Level
- STHO $8.01
- TCRX $1.70
- Resistance Level
- STHO $8.39
- TCRX $2.40
- Average True Range (ATR)
- STHO 0.27
- TCRX 0.16
- MACD
- STHO -0.08
- TCRX 0.03
- Stochastic Oscillator
- STHO 19.20
- TCRX 46.56
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.